Search results
Results From The WOW.Com Content Network
Gambro is a global medical technology company that manufactures products for dialysis treatment. The company is involved in developing, manufacturing and supplying products and therapies for kidney and liver dialysis, myeloma kidney therapy [ clarify ] , and other extracorporeal therapies for chronic and acute patients.
Gambro opened its first dialysis clinic in Lund in 1991. The clinic activities expanded under the name Gambro Healthcare and by 2005 the company managed 150 dialysis clinics worldwide. Gambro Healthcare was divested from Gambro in 2007 and taken over by Bridgepoint Capital, a major private healthcare investor in Europe, and the company ...
In addition, Baxter will build upon its core portfolio and pipeline of investigational home hemodialysis (HD) and automated PD systems by adding Gambro's dialyzers, devices and dialysis solutions ...
On February 27, 1998, the company acquired Renal Treatment Centers for $1.3 billion in stock. [5] [8] The integration went poorly and in July 1999, the CEO and CFO resigned. After tripling in value between 1995 and 1998, by July 1999, the stock price was down 71% year-to-date. [9] [10] In October 1999, Kent J. Thiry, then 43 years old, was ...
Baxter International (NYS: BAX) announced today that it has agreed to buy privately held dialysis systems maker Gambro AB for approximately $4 billion in total consideration. In a statement ...
Centers for Dialysis Care; Concerto Renal Services; DaVita Inc. Diversified Specialty Institute Holdings, Inc. Dialysis Clinic, Inc; Evergreen Nephrology; Fresenius Medical Care; Holy Cross Renal Center; Legacy Dialysis; Liberty Home Dialysis; National Renal Care; Northwest Kidney Centers; Olympus Dialysis [https://www.premierdialysismi.com ...
Hospice Advantage of Pelham. Hospice Advantage, LLC purchased Hospice Care of Pelham from HC Healthcare, Inc. on April 1, 2012. Two years later, on April 14, 2014, an initial Hospice Accreditation survey with the Community Health Accreditation Program (CHAP) was held.
In 1981, Gambro "diversified into the heart-lung product area and built up a special network of suppliers", [10] developing other technologies for treating blood outside the body (extracorporeally), for example in connection with heart surgery, and blood component technology, which separates blood into different components and then uses some of ...